logo
Plus   Neg
Share
Email

Gilead To Present New Data From Its HIV Research & Development Program - Quick Facts

Gilead Sciences, Inc. (GILD) announced that new data from the company's HIV research and development program will be presented at the 23rd International AIDS Conference. Phase 1 trial results supporting further evaluation of a six-month dosing interval for a sustained delivery formulation of Gilead's investigational HIV-1 capsid inhibitor, lenacapavir (GS-6207), will be presented at the Conference.

The company said the HIV treatment data to be presented includes a pooled analysis of four international trials evaluating the safety and efficacy of Biktarvy in adults aged 65 or older.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Pfizer said Friday it reached a multi-year deal with Gilead Sciences to manufacture and supply Gilead's investigational antiviral remdesivir for COVID-19 patients. Ferring Pharmaceuticals US is recalling various nasal sprays citing superpotency or amounts of desmopressin higher than specified, the U.S. Food and Drug Administration announced in a statement. The recall involves all lots on the market of DDAVP Nasal Spray 10 mcg/0.1mL, Desmopressin Acetate Nasal Spray 10 mcg/0.1mL, and STIMATE Nasal Spray 1.5 mg/mL. U.S. President Donald Trump has issued executive orders to ban Chinese mobile application TikTok as well as WeChat, citing a threat to national security and its economy. China's ByteDance Ltd. owns TikTok, a video-sharing mobile app, while Tencent Holdings Ltd. owns WeChat, a messaging, social media, and electronic payment app.
Follow RTT